Breaking News Instant updates and real-time market news.

Intuitive Surgical reports Q3 EPS $6.19, consensus $5.13

Reports Q3 revenue $683M, consensus $650.49M.

18

Oct

29

Nov

ISRGIntuitive Surgical

$721.73

12.29 (1.73%)

09/15/16

SBSH

09/15/16NO CHANGESBSHBuy

New prostate study a positive for Intuitive Surgical, says Citi

Citi analyst Amit Hazan noted that a new study published in the New England Journal of Medicine found no difference in mortality between prostrate cancer patients treated with surgery or radiation and those placed on active monitoring after 10 years. However, men assigned to active monitoring were significantly more likely to have metastatic disease, Hazan highlighted, calling the study a positive for Intuitive Surgical, as it may help doctors "swing the pendulum" back to treatment. The analyst, who thinks Intuitive's da Vinci Prostatectomy procedures can grow above incidence rates for several years, keeps a Buy rating on the stock.

09/19/16

LEER

09/19/16NO CHANGETarget $780LEEROutperform

Leerink positive on Intuitive Surgical's hernia opportunity

Leerink analyst Richard Newitter says he left this weekend's Annual Global Symposium on Robotic-Assisted and Minimally Invasive Hernia Repair "incrementally more positive" on the adoption outlook for Intuitive Surgical's robotic hernia category. Hernia can remain a source of upside for the company's gen surgery division, Newitter tells investors in a research note. He reiterates an Outperform rating on the shares with a $780 price target.

09/20/16

SBSH

09/20/16NO CHANGETarget $779SBSHBuy

Intuitive Surgical procedure upside looks likely, says Citi

Following his firm's semi-annual urology survey and gynecology survey, Citi analyst Amit Hazan believes more procedure upside for Intuitive Surgical looks likely. The results point to continued strength in Intuitive's legacy categories that make up nearly 70% of its U.S. procedures, Hazan tells investors in a research note. He keeps a Buy rating on the shares with a $779 price target.

10/13/16

WELS

10/13/16INITIATIONWELSOutperform

Intuitive Surgical initiated with an Outperform at Wells Fargo

Wells Fargo analyst Larry Biegelsen started Intuitive Surgical with an Outperform rating and $815-$825 price target range. The analyst expects continued adoption of hernia repair and colorectal procedures to drive "strong growth" in the United States and views the company's international opportunity as underappreciated. Biegelsen sees "several reasons" for why Intuitive's share outperformance to continue.

UP AFTER EARNINGS: Cintas (CTAS), up 2.9%... Micron (MU), up 2.8%. ALSO HIGHER: Editas Medicine (EDIT), up 3.1% after it received the EMA's orphan medicinal product designation for EDIT-101... Twitter (TWTR), up 1.8% after it said it will start testing longer, 280-character tweets with a small group. DOWN AFTER EARNINGS: Nike (NKE), down 3.2%. ALSO LOWER: Kornit Digital (KRNT), down 12.2% after it cut its third quarter revenue guidance... Westlake Chemical Partners (WLKP), down 8.3% after it filed to sell 4.5M units for limited partners... Intra-Cellular (ITCI), down 7.2% after it filed to sell $150M in common stock... Ascendis Pharma (ASND), down 4.3% after it announced an offering of $125M of ADSs.